Stellantis Q2 Stabilization Signals Recovery Potential, but Fragility Persists

What happened

Stellantis’ 80% stock decline from its 2024 peak has priced in deep distress, but Q2 2025 results offered early signs of stabilization with North America returning to profitability and industrial metrics improving. Europe remained loss‑making and U.S. dealer inventory climbed to 92 days, underscoring the recovery’s fragility. The green shoots align with the base‑case assumption of a gradual U.S. product‑led turnaround, yet structural European overcapacity continues to weigh. H2 2025 results will be critical to confirm sustained margin and cash‑flow momentum. Without that evidence, the current price may still represent a value trap rather than a genuine bargain.

Implication

Early improvement in Q2 marginally de‑risks the base‑case recovery, but Europe’s persistent losses and high U.S. inventory keep the cheap‑multiple stock vulnerable if execution falters. Investors should monitor H2 industrial free cash flow and margin trends before increasing exposure, as the price embeds a recovery that is not yet assured. The upcoming Capital Markets Day will be a key catalyst to validate strategic direction.

Thesis delta

The Q2 stabilization provides the first tangible evidence supporting the thesis of a slow North American rebound, though it does not shift the WAIT rating. European drag and inventory risk remain, keeping the focus on H2 execution and the 2026 Capital Markets Day to determine whether the stock’s low valuation is justified or a trap.